The Laboratory of Dr. Philip Greenberg is located at the Fred Hutchinson Cancer Research Center, in the clinical division, at the University of Washington and on 1616 Fairview Ave N in Seattle, Washington. We are part of the Program in Immunology.
The Program in Immunology focuses on elucidating the immunobiology of viral and malignant diseases, and developing cellular and molecular strategies to manipulate T cell immunity for the treatment of human diseases. Viruses such as CMV and HIV are never eliminated following acute infection, in part because of viral evasion strategies that prevent immunologic recognition and of quantitative and qualitative deficiencies in the immune response. The molecular basis of such virus escape is being studied, and methods are being pursued to isolate T cells with specificity for desirable viral antigens, as well as to introduce genes into T cells to impart improved antiviral activity. Clinical trials are being performed in which such T cells are being cloned and expanded for infusion into patients to treat of CMV and HIV infection.
The identification of potential target antigens in human tumors is greatly facilitating the evolution of T cell therapy as a modality for cancer therapy. Clinical trials are currently underway for malignant melanoma and acute leukemia. In melanoma, autologous T cell clones reactive with melanosomal tumor proteins are being infused into patients. Cellular and molecular techniques are being used to monitor these cells following infusion to define the potential obstacles to T cell elimination of advanced, disseminated disease. In leukemia, patients undergoing allogeneic hematopoietic cell transplantation are being evaluated to identify allelic minor histocompatibility antigens with expression limited to the hematopoietic lineage that might serve as targets for a selective graft versus leukemia effect without toxicity to normal somatic tissues. These and related studies on antigen processing and T cell activation.